Cellular Nanoparticle (CNP) Technology

Cellics Therapeutics technology platform offers
a revolutionary therapeutic approach for complex diseases.

The Cellular Nanoparticle (CNP) Platform Technology was invented by Dr. Liangfang Zhang, the Joan and Irwin Jacobs Chancellor Professor at UC San Diego and the Scientific Founder of Cellics. This technology strips cell membranes from wild-type or engineered human cells, creates nanoparticles, and uses them as therapeutic products or drug delivery vehicles. By leveraging different cell membranes and functional proteins that can be expressed on the cell membranes, the CNP technology can achieve different therapeutic or vaccination results and drug delivery goals.

Without any drug loading in its nanoparticle core and using cell membranes as drug substance, the CNP technology can create Cellular Nanosponges, which leverage surface protein receptors on the cell membranes to absorb and neutralize toxins, inflammatory cytokines, and viruses that attack human cells. We have achieved proof of concept in animal models in a range of disease areas, as shown in the Full Pipeline.

Loading drugs into its nanoparticle core, the CNP technology can be used to significantly improve targeted delivery and intracellular delivery, extend circulation half-life, and increase overall delivery efficiency for small molecules or biologics drugs. For mRNA delivery, CNP coated with engineered cell membranes has been shown to significantly increase endosomal escape efficiency and overall delivery efficiency of mRNA molecules. Proof of Concept studies have been done for many different indications.